Finance
Italy's Recordati targets 2026 core profit increase
Published by Global Banking & Finance Review®
Posted on February 17, 2026
2 min readLast updated: February 17, 2026
Quick Summary
Recordati aims for 2026 profit growth with rare diseases focus, forecasting EBITDA up to 1.03 billion euros and revenue between 2.73 and 2.80 billion euros.
Recordati Aims for Core Profit Growth by 2026 with Rare Disease Focus
Recordati's Financial Outlook and Strategy
Feb 17 (Reuters) - Italian drug maker Recordati forecast on Tuesday a 2026 core profit (EBITDA) between 995 million euros and 1.03 billion euros ($1.18-1.22 billion), after its 2025 results were boosted by its rare diseases segment.
2026 Profit and Revenue Targets
WHY IT'S IMPORTANT
Performance Highlights from 2025
The 2025 performance showed that Recordati's strategic pivot towards rare diseases continues to pay off, with key treatments for endocrine disorders driving growth and helping to insulate the company from broader pricing pressures affecting the European pharmaceutical market and adverse currency movements.
Growth in Rare Diseases Segment
KEY QUOTE
"There is excellent momentum in rare diseases, which continues to be a key driver of growth and value creation for the group," Chief Executive Officer Rob Koremans said in a statement.
2026 GUIDANCE
Recordati targets for 2026 net revenue between 2.73 and 2.80 billion euros with negative currency movements impact of around 3.5%. It also forecast its adjusted net income to land in a range between 655-685 million euros.
BY THE NUMBERS
The Milan-based firm's full-year EBITDA rose 14.5% year-on-year to 991.1 million euros with margin on net revenue of 37.8%. Its revenue grew by 11.8% totalling 2.62 billion euros.
Adjusted net income came in at 651.1 million euros, up by 14.5% yearly. Its rare diseases segment climbed up 29.7% as compared to full year 2024, or 16.6% on a like-for-like basis.
($1 = 0.8454 euros)
(Reporting by Romolo Tosiani in Gdansk; Editing by Matt Scuffham)
Key Takeaways
- •Recordati forecasts 2026 EBITDA between 995 million and 1.03 billion euros.
- •The rare diseases segment is a key growth driver for Recordati.
- •Recordati's 2025 performance was boosted by rare disease treatments.
- •2026 revenue is expected to be between 2.73 and 2.80 billion euros.
- •Negative currency impacts are anticipated at around 3.5%.
Frequently Asked Questions about Italy's Recordati targets 2026 core profit increase
1What is core profit?
Core profit refers to the earnings generated from a company's primary business operations, excluding any income or expenses from non-core activities.
2What is EBITDA?
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure of a company's overall financial performance.
3What is net revenue?
Net revenue is the total income generated from sales after deducting returns, allowances, and discounts. It reflects the actual revenue a company retains.
4What is adjusted net income?
Adjusted net income is a company's net income that has been modified to exclude certain one-time expenses or income, providing a clearer view of ongoing profitability.
